OGN Stock Recent News
OGN LATEST HEADLINES
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) concluded the recent trading session at $10.26, signifying a -1.06% move from its prior day's close.
NEW YORK , Sept. 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Organon & Co. (NYSE: OGN) breached their fiduciary duties to shareholders.
VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce its shares have been qualified to begin trading on the OTCQB® Venture Market ("OTCQB"). Orogen Royalties Inc. begins trading today on OTCQB under the symbol "OGNNF".
All dollar figures expressed in United States dollars unless otherwise stated VANCOUVER, BC / ACCESS Newswire / September 4, 2025 / (TSXV:OGN)(OTC:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that the Company has signed a multi-year Generative Exploration Alliance Agreement (the "Alliance") with a wholly owned subsidiary of South32 Limited ("South32"). The Alliance will focus on generating base metal targets in western North America.
SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).
VANCOUVER, BC / ACCESS Newswire / August 26, 2025 / (TSXV:OGN)(OTC:OGNNF) Orogen Royalties Inc. (formerly 1537944 BC Ltd.) ("Orogen" or the "Company") is pleased to announce strong revenue and cash flow from operations for the second quarter ended June 30, 2025.
SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased shares of Organon & Co. (NYSE: OGN) prior to October 2024 and continue to hold any of those NYSE: OGN shares, also have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines; cost-cutting helps margins, but can't reverse the downward trend in earnings. Valuation discounts already reflect worst-case scenarios; fair value is around $9 per share, leaving little upside unless growth drivers emerge.
Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?